Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s why
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...
Beyond BMI: Global commission proposes new way to diagnose obesity
LONDON: Doctors worldwide should diagnose obesity differently, relying on broader criteria and taking into account when the condition causes ill-health, according to a new framework drawn up by ...
Hosted on MSN22h
Novel Drug Eases Disease Activity in Dermatomyositis
Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...
Pharmaceutical Technology on MSN10h
Lilly gains US FDA approval for Omvoh to treat Crohn’s disease
Eli Lilly has received approval from the US FDA for Omvoh to treat moderately to severely active Crohn's disease in the adult ...
STAT22h
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
Healio2h
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...
cweb9h
Eli Lilly: Dominating the Diabesity Market with Long-Term Growth Potential
BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...
Global experts propose new obesity diagnosis method beyond BMI
BMI has long been considered a flawed measure that can over-diagnose or underdiagnose obesity, which is currently defined as ...